

Resource Summary Report

Generated by [dkNET](#) on Jul 31, 2026

Ms CD4 BUV496 RM4-5 50ug

RRID:AB_2870665

Type: Antibody

Proper Citation

BD Biosciences Cat# 741050, RRID:AB_2870665

Antibody Information

URL: http://antibodyregistry.org/AB_2870665

Proper Citation: BD Biosciences Cat# 741050, RRID:AB_2870665

Target Antigen: CD4

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Ms CD4 BUV496 RM4-5 50ug

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: RM4-5 (aka RM4.5)

Antibody ID: AB_2870665

Vendor: BD Biosciences

Catalog Number: 741050

Record Creation Time: 20250819T232550+0000

Record Last Update: 20250820T051924+0000

Ratings and Alerts

No rating or validation information has been found for Ms CD4 BUV496 RM4-5 50ug.

No alerts have been found for Ms CD4 BUV496 RM4-5 50ug.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Tursi NJ, et al. (2025) Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity. Cell reports. Medicine, 6(4), 102035.

van Elsas MJ, et al. (2024) Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer cell, 42(6), 1032.

Guak H, et al. (2024) Transcriptional programming mediated by the histone demethylase KDM5C regulates dendritic cell population heterogeneity and function. Cell reports, 43(8), 114506.

Mannion J, et al. (2024) A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death. Immunity, 57(7), 1514.

Ramachandran M, et al. (2023) Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer cell, 41(6), 1134.

van Elsas MJ, et al. (2023) Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy. Journal for immunotherapy of cancer, 11(3).

Delacher M, et al. (2021) Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T??cells. Immunity, 54(4), 702.